HRP20251152T1 - Formulacije/pripravci koji sadrže inhibitor btk-a - Google Patents
Formulacije/pripravci koji sadrže inhibitor btk-aInfo
- Publication number
- HRP20251152T1 HRP20251152T1 HRP20251152TT HRP20251152T HRP20251152T1 HR P20251152 T1 HRP20251152 T1 HR P20251152T1 HR P20251152T T HRP20251152T T HR P20251152TT HR P20251152 T HRP20251152 T HR P20251152T HR P20251152 T1 HRP20251152 T1 HR P20251152T1
- Authority
- HR
- Croatia
- Prior art keywords
- weight
- tablet formulation
- pharmaceutical composition
- ibrutinib
- crospovidone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621001987 | 2016-01-19 | ||
| EP17700821.6A EP3405178B1 (en) | 2016-01-19 | 2017-01-18 | Formulations/compositions comprising a btk inhibitor |
| PCT/EP2017/050964 WO2017125424A1 (en) | 2016-01-19 | 2017-01-18 | Formulations/compositions comprising a btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20251152T1 true HRP20251152T1 (hr) | 2025-12-05 |
Family
ID=57851068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20251152TT HRP20251152T1 (hr) | 2016-01-19 | 2017-01-18 | Formulacije/pripravci koji sadrže inhibitor btk-a |
Country Status (25)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2875986C (en) | 2012-06-04 | 2020-06-09 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| IL315294A (en) * | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| ES3041841T3 (en) * | 2016-01-19 | 2025-11-14 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a btk inhibitor |
| WO2018065504A1 (en) | 2016-10-06 | 2018-04-12 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a btk inhibitor |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2019142207A1 (en) | 2018-01-20 | 2019-07-25 | Natco Pharma Limited | Pharmaceutical compositions comprising ibrutinib |
| EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
| US12201690B2 (en) | 2018-06-15 | 2025-01-21 | Janssen Pharmaceutica Nv | Formulations/compositions comprising ibrutinib |
| US10688050B1 (en) * | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| BR112022007468A2 (pt) * | 2019-10-21 | 2022-07-12 | Celgene Corp | Composições farmacêuticas compreendendo (s)-2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona e métodos para usar as mesmas |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| WO1993009785A1 (en) | 1991-11-22 | 1993-05-27 | Procter & Gamble Pharmaceuticals, Inc. | Risedronate delayed-release compositions |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| ES2180548T3 (es) | 1992-10-16 | 2003-02-16 | Nippon Shinyaku Co Ltd | Metodo de obtencion de matrices de cera. |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| KR19990014865A (ko) | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| EP2157524A3 (en) | 2003-09-03 | 2010-12-08 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| NZ601278A (en) | 2006-09-22 | 2013-09-27 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| WO2013059738A2 (en) * | 2011-10-19 | 2013-04-25 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| CA2875986C (en) | 2012-06-04 | 2020-06-09 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| US20150140085A1 (en) * | 2012-06-29 | 2015-05-21 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| CA2902613A1 (en) * | 2013-03-14 | 2014-10-02 | Pharmacyclics Llc | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors |
| WO2015071432A1 (en) | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
| CN104523695A (zh) * | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
| ES3041841T3 (en) | 2016-01-19 | 2025-11-14 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a btk inhibitor |
| MX2018008771A (es) * | 2016-01-19 | 2018-11-09 | Janssen Pharmaceutica Nv | Formulaciones/composiciones que comprenden un inhibidor de btk. |
-
2017
- 2017-01-18 ES ES17700821T patent/ES3041841T3/es active Active
- 2017-01-18 WO PCT/EP2017/050964 patent/WO2017125424A1/en not_active Ceased
- 2017-01-18 BR BR112018014540-8A patent/BR112018014540B1/pt active IP Right Grant
- 2017-01-18 HK HK19101845.4A patent/HK1259441A1/zh unknown
- 2017-01-18 SM SM20250360T patent/SMT202500360T1/it unknown
- 2017-01-18 LT LTEPPCT/EP2017/050964T patent/LT3405178T/lt unknown
- 2017-01-18 PT PT177008216T patent/PT3405178T/pt unknown
- 2017-01-18 MA MA43650A patent/MA43650B1/fr unknown
- 2017-01-18 DK DK17700821.6T patent/DK3405178T3/da active
- 2017-01-18 PL PL17700821.6T patent/PL3405178T3/pl unknown
- 2017-01-18 JP JP2018556012A patent/JP7336195B2/ja active Active
- 2017-01-18 KR KR1020257004789A patent/KR20250025518A/ko active Pending
- 2017-01-18 EP EP17700821.6A patent/EP3405178B1/en active Active
- 2017-01-18 MX MX2018008772A patent/MX2018008772A/es unknown
- 2017-01-18 CN CN202210154359.9A patent/CN114681462A/zh active Pending
- 2017-01-18 CN CN201780006739.5A patent/CN108472258B/zh active Active
- 2017-01-18 CA CA3008576A patent/CA3008576A1/en active Pending
- 2017-01-18 SI SI201731626T patent/SI3405178T1/sl unknown
- 2017-01-18 EA EA201891664A patent/EA201891664A1/ru unknown
- 2017-01-18 HK HK19101837.4A patent/HK1259433A1/zh unknown
- 2017-01-18 KR KR1020187023229A patent/KR20180102150A/ko active Pending
- 2017-01-18 AU AU2017208473A patent/AU2017208473B2/en active Active
- 2017-01-18 RS RS20250946A patent/RS67236B1/sr unknown
- 2017-01-18 EP EP25183977.5A patent/EP4663247A2/en active Pending
- 2017-01-18 US US16/071,453 patent/US20190290650A1/en not_active Abandoned
- 2017-01-18 HR HRP20251152TT patent/HRP20251152T1/hr unknown
- 2017-01-18 FI FIEP17700821.6T patent/FI3405178T3/fi active
- 2017-01-19 AR ARP170100142A patent/AR107392A1/es unknown
- 2017-01-19 TW TW106101787A patent/TWI794153B/zh not_active IP Right Cessation
-
2018
- 2018-07-17 MX MX2022006817A patent/MX2022006817A/es unknown
-
2021
- 2021-02-11 US US17/174,305 patent/US20210169888A1/en not_active Abandoned
-
2022
- 2022-04-07 JP JP2022063752A patent/JP7565971B2/ja active Active
- 2022-11-22 US US17/992,348 patent/US20230364090A1/en not_active Abandoned
-
2024
- 2024-06-05 JP JP2024091441A patent/JP2024138243A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20251152T1 (hr) | Formulacije/pripravci koji sadrže inhibitor btk-a | |
| AU2019272064B2 (en) | High dosage strength tablets of rucaparib | |
| JP2019506450A5 (cg-RX-API-DMAC7.html) | ||
| Bushra et al. | Formulation development and optimization of ibuprofen tablets by direct compression method | |
| ES2379075T3 (es) | Proceso y aparato para granulación húmeda continua de material en polvo | |
| HRP20100674T1 (hr) | Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka | |
| RU2004123624A (ru) | Сухие гранулированные композиции азитромицина | |
| JP2019506387A5 (cg-RX-API-DMAC7.html) | ||
| US10947244B2 (en) | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations | |
| MY136524A (en) | New solid pharmaceutical formulations comprising telmisartan and preparation thereof | |
| RU2017133990A (ru) | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона | |
| WO2012164578A1 (en) | Compositions and methods for preparing immediate release formulations of nilotinib | |
| KR20160058763A (ko) | 암로디핀 및 발사르탄를 함유하는 안정적인 약제학적 조성물 | |
| RU2010148536A (ru) | Способ непрерывного изготовления фармацевтических композиций | |
| JP2014162743A (ja) | 固形製剤 | |
| Kuno et al. | Effect of preparation method on properties of orally disintegrating tablets made by phase transition | |
| Tran et al. | Modulation of drug crystallization and molecular interactions by additives in solid dispersions for improving drug bioavailability | |
| WO2007086891A1 (en) | Levetiracetam formulations and methods for their manufacture | |
| JP2019011324A (ja) | 医薬組成物 | |
| JP2019011326A (ja) | 医薬組成物 | |
| JP2019089758A (ja) | セレコキシブ含有錠剤における溶出性の改善方法 | |
| CN103877064B (zh) | 一种非诺贝特胶囊剂及其制备工艺 | |
| RU2010129544A (ru) | Фармацевтическая композиция | |
| JP6304751B2 (ja) | ワルファリン含有固形製剤及びその製造方法 | |
| JP2022136252A (ja) | エゼチミブ含有経口製剤及びその製造方法 |